newsfilter
← Latest News
PR Newswire·

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

  • Neurocrine Biosciences executives will attend the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026.
  • The conference presentation is scheduled for 3:30 p.m. GMT (10:30 a.m. ET) on November 17, 2026.
  • A webcast of the event will be accessible via the company's investor website at www.neurocrine.com.
  • A replay of the webcast will be available approximately one hour after the event \& archived for roughly one month.
  • Neurocrine Biosciences holds FDA-approved treatments for tardive dyskinesia, Huntington's chorea, congenital adrenal hyperplasia, Prader-Willi hyperphagia, endometriosis, \& uterine fibroids.
  • The company's endometriosis \& uterine fibroid treatments are developed in collaboration with AbbVie.
  • Neurocrine maintains a pipeline of multiple compounds in mid- to late-phase clinical development across neurological, psychiatric, endocrine, \& immunological disorders.
Company
Neurocrine Biosciences, Inc.
Keywords
Neurocrine Biosciences, Inc.